A group of prominent biotech venture investors appears to be backing a new company built around an experimental eye disease drug developed in Korea, according to Endpoints News.
The report names RA Capital, Forbion and Sanofi Ventures as the investors involved. Endpoints notes that RA Capital and Forbion are not new partners — the two firms have teamed up on a couple of biotech launches in recent quarters.
According to Endpoints, the deal fits a broader pattern it has been tracking: big-name venture investors banding together to launch new companies around an experimental medicine that was originally developed by another biotech. In other words, rather than starting from scratch, well-funded backers are building fresh companies around promising drugs that already exist, in this case one originating from Korea.
Details beyond the investors and the drug's origin are limited in the source, which frames the move as an apparent backing rather than a fully confirmed, finalized financing.
Why it matters: when marquee investors like RA Capital, Forbion and Sanofi Ventures pool their money behind a single experimental drug, it signals where smart biotech capital sees the next opportunities — and increasingly, that search is reaching beyond the usual US and European labs to medicines developed in places like Korea.